• Read more about IOV-LUN-202

Short Title: IOV-LUN-202

This study is to evaluate the efficacy of LN-145 in patients with metastatic NSCLC without an actionable driver mutation who have disease progression on or following a single line of approved systemic therapy consisting of combined immune checkpoint inhibitor(s) (CPI[s]) + chemotherapy ± bevacizumab.

Cohort 1, Cohort 2, and Cohort 4 are open:

Cohort 1: Patients whose tumors did not express programmed cell death-ligand 1 (PD-L1), ie, tumor proportion score (TPS) <1%, prior to ICI treatment and patients with no available historical TPS 

Cohort 2: Patients whose tumors expressed PD-L1 (TPS ≥1%) prior to ICI treatment 

Cohort 4: Patients, regardless of tumor PD-L1 expression status prior to ICI treatment, who had pre-progression tumor harvest 

Study Number:

IOV-LUN-202

Study Status:

Enrolling

Treatment Agent:

Lifileucel, LN-145, Pembrolizumab, LN-145-S1, Ipilimumab, Nivolumab

Resources and Links

National Clinical Trial Identified Number: NCT04614103

Disease:

• Non-Small Cell Lung Cancer

Study Phase:

II

ResearchCancer@CooperHealth.edu

Index Extra:

lung, thoracic

Hide from Search:

Off

Physician Name:

• Young Ki Hong, MD, MPH, FACS, FSSO

Department:

• Lung Cancer Center

• Read more about DRAMMATIC

Short Title: DRAMMATIC/S1803

This clinical trial offers treatment to patients with multiple myeloma who have undergone ASCT, a type of transplant that uses a patient's own stem cells (cells in the bone marrow that produce new blood cells) to replace those normal cells that are damaged by the high dose chemotherapy treatment that is given to kill cancer cells. Because there is a possibility of cancer returning even after ASCT, patients typically receive maintenance treatment, with the goal of preventing or delaying the return of cancer. In this clinical trial, one group of patients will be randomly assigned to receiving the standard maintenance treatment for multiple myeloma — an immunomodulatory drug called lenalidomide - which works by stimulating cells in the immune system, decreasing the blood supply to tumors, and inhibiting the growth of cancer cells.

Please note that this study is approaching the protocol specific accrual goal for Registration Step 1 and will permanently close on January 15th at 12:00 PM PST.

Study Number:

S1803

Study Status:

Enrolling

Treatment Agent:

Lenalidomide, Daratumumab/rHuPH20

Resources and Links

National Clinical Trial Identified Number: NCT04071457

Disease:

• Multiple Myeloma

Study Phase:

III

ResearchCancer@CooperHealth.edu

Index Extra:

Myeloma, HEM

Hide from Search:

Off

Physician Name:

• Tulin Budak-Alpdogan, MD

Department:

• Hematology and Medical Oncology

• Read more about Oral 3D Stent

Short Title: Oral 3D Stent

The primary objective of this randomized trial is to evaluate the acute mucositis rates in non-target mucosa of patients who receive head and neck radiation with or without a customized 3D printed oral stent.

Study Number:

2020-1153

Study Status:

Enrolling

Treatment Agent:

Not Applicable

Resources and Links

National Clinical Trial Identified Number: NCT04870762

Disease:

• Head and Neck Carcinoma

Study Phase:

Not Applicable

ResearchCancer@CooperHealth.edu

Index Extra:

Head and Neck

Hide from Search:

Off

Physician Name:

• Megan Mezera, MD

Department:

• Radiation Oncology

• Read more about Bone Sarcoma

Short Title: PA14-1067

The objectives of the study are to better understand the role of genomic alterations in bone sarcoma patients whose cancers have either progressed on therapy, after a period of response, or were refractory to initial "first-line" treatment.

Study Number:

PA14-1067

Study Status:

Enrolling

Treatment Agent:

Not Applicable

Resources and Links

National Clinical Trial Identified Number: N/A

Disease:

• Bone Sarcoma

Study Phase:

Not Applicable

ResearchCancer@CooperHealth.edu

Index Extra:

Bone, Orthopedic

Hide from Search:

Off

Physician Name:

• Tae Won B. Kim, MD

Department:

• Orthopaedic Program,
• Surgical Oncology,
• Orthopaedic Oncology,
• Rare Cancers Program

• Read more about Guidance

Short Title: Guidance/GU010

This phase III trial uses the Decipher risk score to guide intensification (for higher Decipher gene risk) or de-intensification (for low Decipher gene risk) of treatment to better match therapies to an individual patient's cancer aggressiveness. The Decipher risk score evaluates a prostate cancer tumor for its potential for spreading. In patients with low risk scores, this trial compares radiation therapy alone to the usual treatment of radiation therapy and hormone therapy (androgen deprivation therapy).

Study Number:

GU010

Study Status:

Enrolling

Treatment Agent:

Bicalutamide, Buserelin, Darolutamide, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide

Resources and Links

National Clinical Trial Identified Number: NCT05050084

Disease:

• Prostate Cancer

Study Phase:

III

ResearchCancer@CooperHealth.edu

Index Extra:

Prostate, GU

Hide from Search:

Off

Physician Name:

• Gary A. Eastwick, MD

Department:

• Radiation Oncology

• Read more about PREDICT-RT

Short Title: PREDICT-RT/GU009

This phase III trial compares less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating patients with high risk prostate cancer and low gene risk score. This trial also compares more intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in patients with high risk prostate cancer and high gene risk score.

Study Number:

GU009

Study Status:

Enrolling

Treatment Agent:

Apalutamide, Bicalutamide, Buserelin, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide

Resources and Links

National Clinical Trial Identified Number: NCT04513717

Disease:

• Prostate Cancer

Study Phase:

III

ResearchCancer@CooperHealth.edu

Index Extra:

GU, Prostate

Hide from Search:

Off

Physician Name:

• Gary A. Eastwick, MD

Department:

• Radiation Oncology

• Read more about High-Risk Colorectal Cancer Registry Program

The purpose of this registry is to create and maintain a prospective and retrospective database of patients with early-onset colorectal cancer or who are at increased risk for colorectal cancer based on germline gene mutation status, personal history of cancer, and/or family history of cancer.

Study Status:

Enrolling

Treatment Agent:

Not Applicable

Resources and Links

National Clinical Trial Identified Number: N/A

Disease:

• Colorectal Cancer

Study Phase:

Not Applicable

ResearchCancer@cooperhealth.edu

Index Extra:

GI, Colorectal, gastro

Hide from Search:

Off

Physician Name:

• Steven J McClane, MD, FACS, FASCRS

Department:

• Hematology and Medical Oncology

• Read more about High-Risk Breast Cancer Registry

The purpose of this registry is to collect data on patients at high risk for breast cancer or who have been diagnosed with breast cancer at MD Anderson Cancer Center at Cooper. The importance of the registry is to create a single institution database of individuals (men or women) at increased risk for developing breast cancer or individuals who have had a prior history of breast cancer. The data provided by a site-specific cancer registry can play a significant role in future planning of cancer control programs, in screening and early detection, and in contributing to improved breast cancer care.

Study Status:

Enrolling

Treatment Agent:

Not Applicable

Resources and Links

National Clinical Trial Identified Number: N/A

Disease:

• Breast Cancer

Study Phase:

Not Applicable

ResearchCancer@cooperhealth.edu

Hide from Search:

Off

Physician Name:

• Catherine E. Loveland-Jones, MD, MS, FACS

Department:

• Breast Cancer Center

• Read more about Financial Toxicity

Short Title: Financial Toxicity

This study investigates the impact of COVID-19 pandemic on out-of-pocket costs, lost wages, and unemployment in patients with breast cancer undergoing breast surgery. Post-mastectomy reconstructive patients are at high risk for financial toxicity (adverse effects of escalating health care cost on well-being). 

Study Number:

PA18-1077

Study Status:

Enrolling

Treatment Agent:

Not Applicable

Resources and Links

National Clinical Trial Identified Number: NCT04169542

Disease:

• Breast Cancer

Study Phase:

Not Applicable

ResearchCancer@cooperhealth.edu

Index Extra:

breast

Hide from Search:

Off

Physician Name:

• Steven C. Bonawitz, MD, FACS

Department:

• Plastic and Reconstructive Surgery,
• Breast Cancer Center